Zobrazeno 1 - 10
of 525
pro vyhledávání: '"Masayuki Hino"'
Autor:
Joji Nagasaki, Mitsutaka Nishimoto, Hideo Koh, Hiroshi Okamura, Mika Nakamae, Kazuki Sakatoku, Kentaro Ido, Masatomo Kuno, Yosuke Makuuchi, Teruhito Takakuwa, Yasuhiro Nakashima, Masayuki Hino, Hirohisa Nakamae
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/08be12c9280347749932318cb057c123
Autor:
Yusuke Murakami, Tadao Morino, Masayuki Hino, Hiroshi Misaki, Tomofumi Kinoshita, Masaki Takao
Publikováno v:
Spine Surgery and Related Research, Vol 7, Iss 5, Pp 443-449 (2023)
Introduction: Some patients who have not been diagnosed with diffuse idiopathic skeletal hyperostosis (DISH) (patients in the preclinical stage of DISH [pre-DISH]) may develop DISH in the future. However, there are currently no clearly defined diagno
Externí odkaz:
https://doaj.org/article/44640e0d0219469b8ebf5f494695c1e1
Autor:
Yutaka Shimazu, Junya Kanda, Satoru Kosugi, Tomoki Ito, Hitomi Kaneko, Kazunori Imada, Yuji Shimura, Shin-ichi Fuchida, Kentaro Fukushima, Hirokazu Tanaka, Satoshi Yoshihara, Kensuke Ohta, Nobuhiko Uoshima, Hideo Yagi, Hirohiko Shibayama, Ryosuke Yamamura, Yasuhiro Tanaka, Hitoji Uchiyama, Yoshiyuki Onda, Yoko Adachi, Hitoshi Hanamoto, Ryoichi Takahashi, Mitsuhiro Matsuda, Takashi Miyoshi, Teruhito Takakuwa, Masayuki Hino, Naoki Hosen, Shosaku Nomura, Chihiro Shimazaki, Itaru Matsumura, Akifumi Takaori-Kondo, Junya Kuroda
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Novel therapeutic drugs have dramatically improved the overall survival of patients with multiple myeloma. We sought to identify the characteristics of patients likely to exhibit a durable response to one such drug, elotuzumab, by analyzing
Externí odkaz:
https://doaj.org/article/f9f360c7a7b8496ea74ce32ada6c5c4d
Autor:
Daiki Mukai, Naonori Harada, Ikumi Shibano, Yusuke Kizawa, Hiroshi Shiragami, Atsuko Mugitani, Masayuki Hino
Publikováno v:
eJHaem, Vol 4, Iss 3, Pp 865-866 (2023)
Externí odkaz:
https://doaj.org/article/02747bb3c8c84209a4b39ff71afa3ac1
Autor:
Mitsutaka Nishimoto, Takahiko Nakane, Hideo Koh, Yasuhiro Nakashima, Ryosuke Yamamura, Hirohisa Nakamae, Masayuki Hino, Kensuke Ohta
Publikováno v:
Hematology Reports, Vol 14, Iss 2, Pp 165-171 (2022)
Adult-onset primary autoimmune neutropenia (AIN) is an extremely rare but sometimes life-threatening disease. Its pathophysiology is still to be clarified. We describe a case with adult-onset primary AIN with phagocytosis of mature granulocytes by ma
Externí odkaz:
https://doaj.org/article/e707041793c34d3eb8afd7e923c5d910
Autor:
Aya Nakaya, Hirohiko Shibayama, Nobuhiko Uoshima, Ryosuke Yamamura, Satoshi Yoshioka, Kazunori Imada, Yuji Shimura, Masaaki Hotta, Toshimitsu Matsui, Satoru Kosugi, Hitoshi Hanamoto, Hitoji Uchiyama, Satoshi Yoshihara, Shin-ichi Fuchida, Yoshiyuki Onda, Yasuhiro Tanaka, Kensuke Ohta, Mitsuhiro Matsuda, Junya Kanda, Adachi Yoko, Miki Kiyota, Eri Kawata, Ryoichi Takahashi, Kentaro Fukushima, Hirokazu Tanaka, Hideo Yagi, Teruhito Takakuwa, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Akifumi Takaori-Kondo, Junya Kuroda, Itaru Matsumura, Masayuki Hino
Publikováno v:
Leukemia Research Reports, Vol 20, Iss , Pp 100395- (2023)
To evaluate the specific prognostic value of CAs, we conducted an analysis of 923 symptomatic multiple myeloma patients. Among this cohort, 480 patients had complete data set of high-risk CAs by interphase fluorescent in situ hybridization at diagnos
Externí odkaz:
https://doaj.org/article/82b016d7b6d64623a8db970348a6c492
Autor:
Yutaka Shimazu, Junya Kanda, Hitomi Kaneko, Kazunori Imada, Ryosuke Yamamura, Satoru Kosugi, Yuji Shimura, Tomoki Ito, Shin-ichi Fuchida, Hitoji Uchiyama, Kentaro Fukushima, Satoshi Yoshihara, Hitoshi Hanamoto, Hirokazu Tanaka, Nobuhiko Uoshima, Kensuke Ohta, Hideo Yagi, Hirohiko Shibayama, Yoshiyuki Onda, Yasuhiro Tanaka, Yoko Adachi, Mitsuhiro Matsuda, Masato Iida, Takashi Miyoshi, Toshimitsu Matsui, Ryoichi Takahashi, Teruhito Takakuwa, Masayuki Hino, Naoki Hosen, Shosaku Nomura, Chihiro Shimazaki, Itaru Matsumura, Akifumi Takaori-Kondo, Junya Kuroda
Publikováno v:
Therapeutic Advances in Hematology, Vol 13 (2022)
Background: Daratumumab is one of the most widely used treatments for relapsed/refractory multiple myeloma (MM) patients. However, not all patients achieve a lasting therapeutic response with daratumumab. Objectives: We hypothesized that a durable re
Externí odkaz:
https://doaj.org/article/de0e47159d65497ba083e4d809b5a35a
Autor:
Aya Nakaya, Hirohiko Shibayama, Eiji Nakatani, Yuji Shimura, Satoru Kosugi, Hirokazu Tanaka, Shin‐Ichi Fuchida, Junya Kanda, Nobuhiko Uoshima, Hitomi Kaneko, Kazunori Imada, Kensuke Ohta, Tomoki Ito, Hideo Yagi, Satoshi Yoshihara, Masayuki Hino, Chihiro Shimazaki, Akifumi Takaori‐Kondo, Junya Kuroda, Itaru Matsumura, Yuzuru Kanakura, Shosaku Nomura
Publikováno v:
eJHaem, Vol 2, Iss 4, Pp 765-773 (2021)
Abstract A total of 129 symptomatic patients with multiple myeloma (MM) who underwent high‐dose chemotherapy with autologous stem cell transplantation (HDT/ASCT) were analyzed. The 4‐year overall survival (OS) of patients with maintenance (n = 82
Externí odkaz:
https://doaj.org/article/fca8d9086da64417a2e3ae2412495e6f
Autor:
Hirohisa Nakamae, Hiroshi Okamura, Asao Hirose, Hideo Koh, Yasuhiro Nakashima, Mika Nakamae, Mitsutaka Nishimoto, Yosuke Makuuchi, Masatomo Kuno, Naonori Harada, Teruhito Takakuwa, Masayuki Hino
Publikováno v:
Cell Transplantation, Vol 31 (2022)
The optimal dose of posttransplant cyclophosphamide (PTCy) for use in patients undergoing HLA-haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide (PTCy-haplo) has not been sufficiently examined. This study evaluates
Externí odkaz:
https://doaj.org/article/286fd7bdcff04bad95b06ad2bf027c4c
Autor:
Yoshiyuki Onda, Junya Kanda, Hitomi Kaneko, Yuji Shimura, Shin-ichi Fuchida, Aya Nakaya, Tomoki Itou, Ryosuke Yamamura, Hirokazu Tanaka, Hirohiko Shibayama, Yutaka Shimazu, Hitoji Uchiyama, Satoshi Yoshihara, Yoko Adachi, Mitsuhiro Matsuda, Hitoshi Hanamoto, Nobuhiko Uoshima, Satoru Kosugi, Kensuke Ohta, Hideo Yagi, Yuzuru Kanakura, Itaru Matsumura, Masayuki Hino, Shosaku Nomura, Chihiro Shimazaki, Akifumi Takaori-Kondo, Junya Kuroda
Publikováno v:
Therapeutic Advances in Hematology, Vol 13 (2022)
Background: Little is known about the real-world survival benefits and safety profiles of carfilzomib–lenalidomide–dexamethasone (KRd) and carfilzomib–dexamethasone (Kd). Methods: We performed a retrospective analysis to evaluate their efficacy
Externí odkaz:
https://doaj.org/article/c8a169335f1a487791719eaf9c1c6082